OncoMatch/Clinical Trials/NCT06084897
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Is NCT06084897 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-1 inhibitor and TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice. for esophageal neoplasm metastatic.
Treatment: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice. · PD-1 inhibitor — The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently. On this basis, the investigators intend to conduct a prospective, multicenter phase II clinical trial to assess whether radiotherapy could further improve the survival of patients with metastatic esophageal cancer responding to PD-1 Inhibitor plus chemotherapy. Accompanied tissue samples, blood samples and urine samples will be analyzed by molecular biological detection (Including Whole Exome Sequencing and proteomics) to explore potential biomarkers for predicting outcomes, efficacy and toxicity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — first-line, combined with immunotherapy
With response to 2-4 cycles of the first-line chemotherapy combined with immunotherapy
Cannot have received: surgery
Exception: ostomy
Received surgery (except ostomy), chemotherapy or other anti-tumor treatment before enrollment
Cannot have received: chemotherapy
Received surgery (except ostomy), chemotherapy or other anti-tumor treatment before enrollment
Cannot have received: other anti-tumor treatment
Received surgery (except ostomy), chemotherapy or other anti-tumor treatment before enrollment
Lab requirements
Blood counts
no significant abnormality in blood routine
Kidney function
no significant abnormality in kidney function
Liver function
no significant abnormality in liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify